eligibility_summary
Adults 18–65, ECOG ≤1, survival >12 wks, relapsed/refractory B‑NHL (FL, MALT, LPL, MCL, SLL, DLBCL/PMBCL/grey zone, Burkitt), prior rituximab and ≥2L, measurable lesion (Lugano 2014), AEs ≤1, adequate hematologic/hepatic/renal, contraception. Exclude recent anticancer/RT/investigational, HSCT/organ/CAR‑T, other cancers, CNS disease, major CV risks, mAb allergy, recent surgery, high‑dose steroids/immunosupp, viral/infection/effusions, pregnancy, noncompliance, live vaccine, or investigator concern.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06565689: Phase 1, open-label, multicenter study in relapsed/refractory B‑cell non-Hodgkin lymphoma evaluating YK012. Intervention: YK012, an intravenously administered bispecific antibody (T‑cell–engaging biologic). Mechanism: simultaneously binds CD19 on B cells and CD3 on T cells to form an immune synapse, triggering TCR/CD3 signaling and T‑cell–mediated cytotoxicity against malignant CD19+ B cells. Targets/cells/pathways: CD19+ B cells (B‑cell lineage marker), CD3 on T cells, activates T‑cell effector pathways to eliminate pathological B cells.